Ginkgo Bioworks DNA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | —— | —— | —— | ||
| $141.31M-37.8% | $160.07M-29.5% | $170.52M-21.8% | $220.73M+19.7% | $227.33M+8.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $222.77M-37.9% | $243.77M-42.5% | $270.02M-41.9% | $277.68M-49.0% | $358.53M-35.3% | ||
| $172.08M-20.2% | $173.97M-29.3% | $185.25M-33.4% | $192.59M-37.4% | $215.6M-37.3% | ||
| —— | —— | —— | —— | —— | ||
| -$297.68M+35.7% | -$307.28M+45.1% | -$340.14M+46.4% | -$305.32M+64.7% | -$462.73M+44.0% | ||
| -210.7%-7.1pp | -192%+54.6pp | -199.5%+91.5pp | -138.3%+331pp | -203.5%+193pp | ||
| —— | —— | —— | —— | —— | ||
| -$298.87M+35.7% | -$305.95M+44.1% | -$332.42M+49.0% | -$308.44M+65.6% | -$464.85M+45.6% | ||
| -$1.01M-138% | -$837K-74.7% | -$519K-47.4% | -$895K-89,600% | -$422K-246% | ||
| -$240.72M+39.5% | -$248.29M+50.0% | -$279.16M+51.4% | -$241.34M+69.9% | -$397.75M+47.8% | ||
| -170.3%+4.6pp | -155.1%+63.7pp | -163.7%+99.7pp | -109.3%+325pp | -175%+190pp | ||
| -$297.68M+35.7% | -$307.28M+45.1% | -$340.14M+46.4% | -$305.32M+64.7% | -$462.73M+44.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ginkgo Bioworks's revenue?
- Ginkgo Bioworks (DNA) generated $141.3M in revenue over the trailing twelve months, down 37.8% year over year.
- Is Ginkgo Bioworks profitable?
- Ginkgo Bioworks is not currently profitable: it reported a net loss of $304.4M over the trailing twelve months, a -215.4% net margin.
- Where does Ginkgo Bioworks's income statement data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
